APO Research
Talk to an analyst

APO RESEARCH · REPORT

DNA Vaccines

The DNA vaccine in this report refers to the vaccines manufactured using recombinant DNA technology. The advent of these vaccines has revolutionized the healthcare market. These vaccines are more effective, as well as have less side-effects associated with them as compared to traditional vaccines.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

The DNA vaccine in this report refers to the vaccines manufactured using recombinant DNA technology. The advent of these vaccines has revolutionized the healthcare market. These vaccines are more effective, as well as have less side-effects associated with them as compared to traditional vaccines.

Selected research

Market Outlook & Growth Opportunities

Global DNA Vaccines Market Outlook and Growth Opportunities 2026

20 December 2025195 pages

Choose your research edition.

Industry ResearchDNA Vaccines Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal DNA Vaccines Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal DNA Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal DNA Vaccines Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal DNA Vaccines Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The DNA vaccine in this report refers to the vaccines manufactured using recombinant DNA technology. The advent of these vaccines has revolutionized the healthcare market. These vaccines are more effective, as well as have less side-effects associated with them as compared to traditional vaccines.

Global direct-to-consumer genetic testing main players include Merck, GSK, Sanofi, Zoties, Elanco, Boehringer-Ingelheim, Indian Immunologicals and Plumbline Life Sciences, etc., totally accounting for about 50% of the market. North America is the largest market, with a share over 95%. As for the types of products, it can be divided into recombinant protein vaccine and gene-based vaccine. The most common product is recombinant protein, with a share over 95%. In terms of applications, it is widely used in human and animal. Human is the largest application, holding a share over 95%.

This report provides an overview of the global DNA Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of DNA Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents DNA Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the DNA Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

DNA Vaccines Segment by Company

Merck

GSK

Sanofi

Zoties

Elanco

Boehringer-Ingelheim

Indian Immunologicals

Plumbline Life Sciences

DNA Vaccines Segment by Type

Recombinant Protein Vaccine

Gene-Based Vaccine

DNA Vaccines Segment by Application

Human

Animal

DNA Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global DNA Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions DNA Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify DNA Vaccines significant trends, drivers, influence factors in global and regions.

6. To analyze DNA Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global DNA Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of DNA Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of DNA Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the DNA Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global DNA Vaccines industry.

Chapter 3: Detailed analysis of DNA Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of DNA Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of DNA Vaccines in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. DNA Vaccines Industry Trends Table 2. DNA Vaccines Industry Drivers Table 3. DNA Vaccines Industry Opportunities and Challenges Table 4. DNA Vaccines Industry Restraints Table 5. Global DNA Vaccines Revenue by Company (US$ Million) & (2021-2026) Table 6. Global DNA Vaccines Revenue Share by Company (2021-2026) Table 7. Global DNA Vaccines Sales Volume by Company (K Doses) & (2021-2026) Table 8. Global DNA Vaccines Sales Volume Share by Company (2021-2026) Table 9. Global DNA Vaccines Average Price (US$/Dose) of Company (2021-2026) Table 10. Global DNA Vaccines Company Ranking, (2024-2026) & (USD Million) Table 11. Global DNA Vaccines Key Company Manufacturing Base & Headquarters Table 12. Global DNA Vaccines Company, Product Type & Application Table 13. Global DNA Vaccines Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global DNA Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Recombinant Protein Vaccine Table 18. Significant Companies of Gene-Based Vaccine Table 19. Global DNA Vaccines Sales Volume by Type 2021 VS 2025 VS 2032 (K Doses) Table 20. Global DNA Vaccines Sales Volume by Type (2021-2026) & (K Doses) Table 21. Global DNA Vaccines Sales Volume by Type (2027-2032) & (K Doses) Table 22. Global DNA Vaccines Sales Volume Share by Type (2021-2026) Table 23. Global DNA Vaccines Sales Volume Share by Type (2027-2032) Table 24. Global DNA Vaccines Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global DNA Vaccines Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global DNA Vaccines Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global DNA Vaccines Sales Value Share by Type (2021-2026) Table 28. Global DNA Vaccines Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Human Table 30. Significant Companies of Animal Table 31. Global DNA Vaccines Sales Volume by Application 2021 VS 2025 VS 2032 (K Doses) Table 32. Global DNA Vaccines Sales Volume by Application (2021-2026) & (K Doses) Table 33. Global DNA Vaccines Sales Volume by Application (2027-2032) & (K Doses) Table 34. Global DNA Vaccines Sales Volume Share by Application (2021-2026) Table 35. Global DNA Vaccines Sales Volume Share by Application (2027-2032) Table 36. Global DNA Vaccines Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global DNA Vaccines Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global DNA Vaccines Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global DNA Vaccines Sales Value Share by Application (2021-2026) Table 40. Global DNA Vaccines Sales Value Share by Application (2027-2032) Table 41. Global DNA Vaccines Sales by Region: 2021 VS 2025 VS 2032 (K Doses) Table 42. Global DNA Vaccines Sales by Region (2021-2026) & (K Doses) Table 43. Global DNA Vaccines Sales Market Share by Region (2021-2026) Table 44. Global DNA Vaccines Sales by Region (2027-2032) & (K Doses) Table 45. Global DNA Vaccines Sales Market Share by Region (2027-2032) Table 46. Global DNA Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global DNA Vaccines Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global DNA Vaccines Sales Value Share by Region (2021-2026) Table 49. Global DNA Vaccines Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global DNA Vaccines Sales Value Share by Region (2027-2032) Table 51. Global DNA Vaccines Market Average Price (US$/Dose) by Region (2021-2026) Table 52. Global DNA Vaccines Market Average Price (US$/Dose) by Region (2027-2032) Table 53. Global DNA Vaccines Sales by Country: 2021 VS 2025 VS 2032 (K Doses) Table 54. Global DNA Vaccines Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global DNA Vaccines Sales by Country (2021-2026) & (K Doses) Table 56. Global DNA Vaccines Sales Market Share by Country (2021-2026) Table 57. Global DNA Vaccines Sales by Country (2027-2032) & (K Doses) Table 58. Global DNA Vaccines Sales Market Share by Country (2027-2032) Table 59. Global DNA Vaccines Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global DNA Vaccines Sales Value Market Share by Country (2021-2026) Table 61. Global DNA Vaccines Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global DNA Vaccines Sales Value Market Share by Country (2027-2032) Table 63. Merck Company Information Table 64. Merck Business Overview Table 65. Merck DNA Vaccines Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 66. Merck DNA Vaccines Product Portfolio Table 67. Merck Recent Development Table 68. GSK Company Information Table 69. GSK Business Overview Table 70. GSK DNA Vaccines Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 71. GSK DNA Vaccines Product Portfolio Table 72. GSK Recent Development Table 73. Sanofi Company Information Table 74. Sanofi Business Overview Table 75. Sanofi DNA Vaccines Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 76. Sanofi DNA Vaccines Product Portfolio Table 77. Sanofi Recent Development Table 78. Zoties Company Information Table 79. Zoties Business Overview Table 80. Zoties DNA Vaccines Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 81. Zoties DNA Vaccines Product Portfolio Table 82. Zoties Recent Development Table 83. Elanco Company Information Table 84. Elanco Business Overview Table 85. Elanco DNA Vaccines Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 86. Elanco DNA Vaccines Product Portfolio Table 87. Elanco Recent Development Table 88. Boehringer-Ingelheim Company Information Table 89. Boehringer-Ingelheim Business Overview Table 90. Boehringer-Ingelheim DNA Vaccines Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 91. Boehringer-Ingelheim DNA Vaccines Product Portfolio Table 92. Boehringer-Ingelheim Recent Development Table 93. Indian Immunologicals Company Information Table 94. Indian Immunologicals Business Overview Table 95. Indian Immunologicals DNA Vaccines Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 96. Indian Immunologicals DNA Vaccines Product Portfolio Table 97. Indian Immunologicals Recent Development Table 98. Plumbline Life Sciences Company Information Table 99. Plumbline Life Sciences Business Overview Table 100. Plumbline Life Sciences DNA Vaccines Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 101. Plumbline Life Sciences DNA Vaccines Product Portfolio Table 102. Plumbline Life Sciences Recent Development Table 103. Key Raw Materials Table 104. Raw Materials Key Suppliers Table 105. DNA Vaccines Distributors List Table 106. DNA Vaccines Customers List Table 107. Research Programs/Design for This Report Table 108. Authors List of This Report Table 109. Secondary Sources Table 110. Primary Sources List of Figures Figure 1. DNA Vaccines Product Image Figure 2. Global DNA Vaccines Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global DNA Vaccines Sales Value (2021-2032) & (US$ Million) Figure 4. Global DNA Vaccines Sales (2021-2032) & (K Doses) Figure 5. Global DNA Vaccines Sales Average Price (US$/Dose) & (2021-2032) Figure 6. Global DNA Vaccines Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Recombinant Protein Vaccine Image Figure 10. Gene-Based Vaccine Image Figure 11. Global DNA Vaccines Sales Volume by Type (2021 VS 2025 VS 2032) & (K Doses) Figure 12. Global DNA Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global DNA Vaccines Sales Volume Share by Type (2021-2032) Figure 14. Global DNA Vaccines Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global DNA Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global DNA Vaccines Sales Value Share by Type (2021-2032) Figure 17. Human Image Figure 18. Animal Image Figure 19. Global DNA Vaccines Sales Volume by Application (2021 VS 2025 VS 2032) & (K Doses) Figure 20. Global DNA Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global DNA Vaccines Sales Volume Share by Application (2021-2032) Figure 22. Global DNA Vaccines Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global DNA Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global DNA Vaccines Sales Value Share by Application (2021-2032) Figure 25. Global DNA Vaccines Sales by Region: 2021 VS 2025 VS 2032 (K Doses) Figure 26. Global DNA Vaccines Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global DNA Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global DNA Vaccines Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America DNA Vaccines Sales Value (2021-2032) & (US$ Million) Figure 30. North America DNA Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe DNA Vaccines Sales Value (2021-2032) & (US$ Million) Figure 32. Europe DNA Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific DNA Vaccines Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific DNA Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America DNA Vaccines Sales Value (2021-2032) & (US$ Million) Figure 36. South America DNA Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa DNA Vaccines Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa DNA Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA DNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA DNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA DNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada DNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada DNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada DNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico DNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico DNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico DNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany DNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany DNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany DNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France DNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France DNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France DNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. DNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. DNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. DNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy DNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy DNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy DNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain DNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain DNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain DNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia DNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia DNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia DNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands DNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands DNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands DNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries DNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries DNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries DNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China DNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China DNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China DNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan DNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan DNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan DNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea DNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea DNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea DNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India DNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India DNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India DNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia DNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia DNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia DNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia DNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia DNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia DNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil DNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil DNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil DNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina DNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina DNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina DNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile DNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile DNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile DNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia DNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia DNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia DNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru DNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru DNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru DNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia DNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia DNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia DNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel DNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia DNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia DNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE DNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE DNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE DNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey DNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey DNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey DNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran DNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran DNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran DNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt DNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt DNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt DNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. DNA Vaccines Value Chain Figure 124. Manufacturing Cost Structure Figure 125. DNA Vaccines Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Recombinant Protein Vaccine
  • Gene-Based Vaccine
Applications
  • Human
  • Animal
Companies covered
  • Merck
  • GSK
  • Sanofi
  • Zoties
  • Elanco
  • Boehringer-Ingelheim
  • Indian Immunologicals
  • Plumbline Life Sciences

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global DNA Vaccines Sales Value (2021-2032)
  4. 1.2.2 Global DNA Vaccines Sales Volume (2021-2032)
  5. 1.2.3 Global DNA Vaccines Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 DNA Vaccines Market Dynamics
  1. 2.1 DNA Vaccines Industry Trends
  2. 2.2 DNA Vaccines Industry Drivers
  3. 2.3 DNA Vaccines Industry Opportunities and Challenges
  4. 2.4 DNA Vaccines Industry Restraints
3 DNA Vaccines Market by Company
  1. 3.1 Global DNA Vaccines Company Revenue Ranking in 2025
  2. 3.2 Global DNA Vaccines Revenue by Company (2021-2026)
  3. 3.3 Global DNA Vaccines Sales Volume by Company (2021-2026)
  4. 3.4 Global DNA Vaccines Average Price by Company (2021-2026)
  5. 3.5 Global DNA Vaccines Company Ranking (2024-2026)
  6. 3.6 Global DNA Vaccines Company Manufacturing Base and Headquarters
  7. 3.7 Global DNA Vaccines Company Product Type and Application
  8. 3.8 Global DNA Vaccines Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global DNA Vaccines Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 DNA Vaccines Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 DNA Vaccines Market by Type
  1. 4.1 DNA Vaccines Type Introduction
  2. 4.1.1 Recombinant Protein Vaccine
  3. 4.1.2 Gene-Based Vaccine
  4. 4.2 Global DNA Vaccines Sales Volume by Type
  5. 4.2.1 Global DNA Vaccines Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global DNA Vaccines Sales Volume by Type (2021-2032)
  7. 4.2.3 Global DNA Vaccines Sales Volume Share by Type (2021-2032)
  8. 4.3 Global DNA Vaccines Sales Value by Type
  9. 4.3.1 Global DNA Vaccines Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global DNA Vaccines Sales Value by Type (2021-2032)
  11. 4.3.3 Global DNA Vaccines Sales Value Share by Type (2021-2032)
5 DNA Vaccines Market by Application
  1. 5.1 DNA Vaccines Application Introduction
  2. 5.1.1 Human
  3. 5.1.2 Animal
  4. 5.2 Global DNA Vaccines Sales Volume by Application
  5. 5.2.1 Global DNA Vaccines Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global DNA Vaccines Sales Volume by Application (2021-2032)
  7. 5.2.3 Global DNA Vaccines Sales Volume Share by Application (2021-2032)
  8. 5.3 Global DNA Vaccines Sales Value by Application
  9. 5.3.1 Global DNA Vaccines Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global DNA Vaccines Sales Value by Application (2021-2032)
  11. 5.3.3 Global DNA Vaccines Sales Value Share by Application (2021-2032)
6 DNA Vaccines Regional Sales and Value Analysis
  1. 6.1 Global DNA Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global DNA Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global DNA Vaccines Sales by Region: 2021-2026
  4. 6.2.2 Global DNA Vaccines Sales by Region (2027-2032)
  5. 6.3 Global DNA Vaccines Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global DNA Vaccines Sales Value by Region (2021-2032)
  7. 6.4.1 Global DNA Vaccines Sales Value by Region: 2021-2026
  8. 6.4.2 Global DNA Vaccines Sales Value by Region (2027-2032)
  9. 6.5 Global DNA Vaccines Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America DNA Vaccines Sales Value (2021-2032)
  12. 6.6.2 North America DNA Vaccines Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe DNA Vaccines Sales Value (2021-2032)
  15. 6.7.2 Europe DNA Vaccines Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific DNA Vaccines Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific DNA Vaccines Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America DNA Vaccines Sales Value (2021-2032)
  21. 6.9.2 South America DNA Vaccines Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa DNA Vaccines Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa DNA Vaccines Sales Value Share by Country, 2025 VS 2032
7 DNA Vaccines Country-level Sales and Value Analysis
  1. 7.1 Global DNA Vaccines Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global DNA Vaccines Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global DNA Vaccines Sales by Country (2021-2032)
  4. 7.3.1 Global DNA Vaccines Sales by Country (2021-2026)
  5. 7.3.2 Global DNA Vaccines Sales by Country (2027-2032)
  6. 7.4 Global DNA Vaccines Sales Value by Country (2021-2032)
  7. 7.4.1 Global DNA Vaccines Sales Value by Country (2021-2026)
  8. 7.4.2 Global DNA Vaccines Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA DNA Vaccines Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA DNA Vaccines Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA DNA Vaccines Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada DNA Vaccines Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada DNA Vaccines Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada DNA Vaccines Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico DNA Vaccines Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico DNA Vaccines Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico DNA Vaccines Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany DNA Vaccines Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany DNA Vaccines Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany DNA Vaccines Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France DNA Vaccines Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France DNA Vaccines Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France DNA Vaccines Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. DNA Vaccines Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. DNA Vaccines Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. DNA Vaccines Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy DNA Vaccines Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy DNA Vaccines Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy DNA Vaccines Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain DNA Vaccines Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain DNA Vaccines Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain DNA Vaccines Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia DNA Vaccines Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia DNA Vaccines Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia DNA Vaccines Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands DNA Vaccines Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands DNA Vaccines Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands DNA Vaccines Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries DNA Vaccines Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries DNA Vaccines Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries DNA Vaccines Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China DNA Vaccines Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China DNA Vaccines Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China DNA Vaccines Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan DNA Vaccines Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan DNA Vaccines Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan DNA Vaccines Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea DNA Vaccines Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea DNA Vaccines Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea DNA Vaccines Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India DNA Vaccines Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India DNA Vaccines Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India DNA Vaccines Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia DNA Vaccines Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia DNA Vaccines Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia DNA Vaccines Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia DNA Vaccines Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia DNA Vaccines Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia DNA Vaccines Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil DNA Vaccines Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil DNA Vaccines Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil DNA Vaccines Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina DNA Vaccines Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina DNA Vaccines Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina DNA Vaccines Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile DNA Vaccines Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile DNA Vaccines Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile DNA Vaccines Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia DNA Vaccines Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia DNA Vaccines Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia DNA Vaccines Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru DNA Vaccines Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru DNA Vaccines Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru DNA Vaccines Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia DNA Vaccines Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia DNA Vaccines Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia DNA Vaccines Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel DNA Vaccines Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel DNA Vaccines Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel DNA Vaccines Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE DNA Vaccines Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE DNA Vaccines Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE DNA Vaccines Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey DNA Vaccines Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey DNA Vaccines Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey DNA Vaccines Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran DNA Vaccines Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran DNA Vaccines Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran DNA Vaccines Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt DNA Vaccines Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt DNA Vaccines Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt DNA Vaccines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck DNA Vaccines Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Merck DNA Vaccines Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 GSK
  8. 8.2.1 GSK Company Information
  9. 8.2.2 GSK Business Overview
  10. 8.2.3 GSK DNA Vaccines Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 GSK DNA Vaccines Product Portfolio
  12. 8.2.5 GSK Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi DNA Vaccines Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi DNA Vaccines Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Zoties
  20. 8.4.1 Zoties Company Information
  21. 8.4.2 Zoties Business Overview
  22. 8.4.3 Zoties DNA Vaccines Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Zoties DNA Vaccines Product Portfolio
  24. 8.4.5 Zoties Recent Developments
  25. 8.5 Elanco
  26. 8.5.1 Elanco Company Information
  27. 8.5.2 Elanco Business Overview
  28. 8.5.3 Elanco DNA Vaccines Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Elanco DNA Vaccines Product Portfolio
  30. 8.5.5 Elanco Recent Developments
  31. 8.6 Boehringer-Ingelheim
  32. 8.6.1 Boehringer-Ingelheim Company Information
  33. 8.6.2 Boehringer-Ingelheim Business Overview
  34. 8.6.3 Boehringer-Ingelheim DNA Vaccines Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Boehringer-Ingelheim DNA Vaccines Product Portfolio
  36. 8.6.5 Boehringer-Ingelheim Recent Developments
  37. 8.7 Indian Immunologicals
  38. 8.7.1 Indian Immunologicals Company Information
  39. 8.7.2 Indian Immunologicals Business Overview
  40. 8.7.3 Indian Immunologicals DNA Vaccines Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Indian Immunologicals DNA Vaccines Product Portfolio
  42. 8.7.5 Indian Immunologicals Recent Developments
  43. 8.8 Plumbline Life Sciences
  44. 8.8.1 Plumbline Life Sciences Company Information
  45. 8.8.2 Plumbline Life Sciences Business Overview
  46. 8.8.3 Plumbline Life Sciences DNA Vaccines Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Plumbline Life Sciences DNA Vaccines Product Portfolio
  48. 8.8.5 Plumbline Life Sciences Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 DNA Vaccines Value Chain Analysis
  2. 9.1.1 DNA Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 DNA Vaccines Sales Mode & Process
  6. 9.2 DNA Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 DNA Vaccines Distributors
  9. 9.2.3 DNA Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst